Prof. Ying Fan 樊英
Chief Physician, Professor
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology with a focus on breast cancer, including chemotherapy, endocrine therapy, and targeted therapy. Also experienced in treating lung cancer and gastrointestinal tumors.
Dr. Fan holds a medical doctorate from Peking Union Medical College (2003) and trained at the Royal Marsden Hospital and National Cancer Institute in the UK (2008-2009). A professor and master's supervisor, Dr. Fan conducts research on personalized treatment and participates in clinical trials for new anti-cancer drugs. Dr. Fan has published over 20 papers and co-authored five books.
Name order: in Chinese the family name comes first (Fan Ying). Papers usually list the name as Ying Fan or Fan Y.
Selected publications
118 papers on PubMed matched by name and affiliation; 22 as first or senior author since 2016. Most recent first- or senior-author papers:
- JAMA, 2026 (first author): Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial. PubMed 42925007
- Breast Cancer Res, 2026 (first author): Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a detailed safety analysis of the randomized OptiTROP-Breast01 study. PubMed 42806387
- Cancer Lett, 2026 (senior author): Spatially resolved transcriptomics identifies tumor-stroma-immune networks and therapeutic targets in endocrine-resistant advanced breast cancer treated with Everolimus+Letrozole: insights from the MIRACLE trial. PubMed 41720449
- Cancer Res Treat, 2026 (senior author): Pre-Treatment Ki67 Index for Everolimus Efficacy in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Multicenter Cohort Study. PubMed 41531150
- Chin J Cancer Res, 2025 (senior author): Factors associated with neoadjuvant therapy insensitivity and its prognostic impact in HER2-positive breast cancer. PubMed 41523841
- MedComm (2020), 2025 (senior author): High-Plex Digital Spatial Profiling Identified Prolactin-Induced Protein mRNA Associated With Response and Survival of Everolimus and Letrozole Treatment for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. PubMed 41322031
- Int J Biol Macromol, 2025 (senior author): Single-cell sequencing exposes mast cell-derived CD52's anti-tumor action in breast cancer through the IL-6/JAK/STAT3 axis. PubMed 40194575
- Thorac Cancer, 2025 (senior author): Clinicopathological Factors That Predict Different Responses of Breast and Axillary Tumors to Neoadjuvant Chemotherapy and Prognosis Among Patients With Node-Positive Breast Cancer: Real World Data. PubMed 40176396
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion